

CB2 Insights Inc.

11:18 11 Dec 2019

Buds & Duds: Cannabis stocks hold steady as small cap stocks find themselves in the green

Cannabis stocks headed into positive territory on Wednesday with all major indices in the green.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.6% higher to 112.1 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF sat flat at C\$9.12, while the OTCQX Cannabis index gained 0.8% to 431.5 points.

Buds

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) climbed Wednesday as it launched a warrant incentive program designed to encourage the exercise of its outstanding warrants.

The company is offering an inducement to warrant holders who exercise their warrants by Christmas. If every warrant is exercised, the company said, CB2 expects to receive nearly \$1.1 million in gross proceeds.

Shares of the data analytics company rose 5.6% in Canada at C\$0.10 and sat at US\$0.08 over the counter.

Choom (CSE:CHOO) (OTCMKTS:CHOO) rocketed higher on the opening of two new cannabis stores in Alberta, the next step in the company's expanding Canadian footprint.

Choom shares raced 13.8% higher in Canada at C\$0.17 and 15.9% over the counter at US\$0.13.

Zenabis Global Inc (TSE:ZENA) (OTCMKTS:ZBISF) also jumped after it announced a new chief executive in Kevin Coft, one of the company's founders, who will take over the role on an interim basis.

Shares of Zenabis were up 5.4% in Toronto at C\$0.20 and trading in the US at US\$0.15.

Duds

Investors sent World Class Extractions Inc (CSE:PUMP) down 17.6% to sit at C\$0.07 on Wednesday after the company announced a new joint venture with Nutralife Holdings LLC to operate a hemp extraction facility in California.

The agreement gives World Class access to the burgeoning US market by offering its hemp extraction and processing services to third parties in the US.

Other companies that found themselves in the red included Hexo Corp (TSE:HEXO) (NYSE:HEXO), which lost 1.6% in Toronto at C\$2.84 and 2.8% in the US at US\$2.12; MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF), down 1.7% at C\$3.37 and 2.3% at US\$2.55; and Khiron Life Sciences Corp (CVE:KHRN), which sank 3.3% to C\$0.88 and 2% at US\$0.68.

Price: 0.085

Market Cap: \$6.8 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: CBII

Listing: CSE

52 week	High	Low
	0.33	0.055

Sector: Cannabis

Website: cb2insights.com

Company Synopsis:

Our mission is to deliver the industry's most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights.

action@proactiveinvestors.com

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).